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Objectives To assess the cost-effectiveness of progesterone
compared with placebo in preventing pregnancy loss in women
with early pregnancy vaginal bleeding.
Design Economic evaluation alongside a large multi-centre
randomised placebo-controlled trial.
Setting Forty-eight UK NHS early pregnancy units.
Population Four thousand one hundred and fifty-three
women aged 16–39 years with bleeding in early
pregnancy and ultrasound evidence of an
intrauterine sac.
Methods An incremental cost-effectiveness analysis was performed
from National Health Service (NHS) and NHS and Personal
Social Services perspectives. Subgroup analyses were carried out
on women with one or more and three or more previous
miscarriages.
Main outcome measures Cost per additional live birth at
≥34 weeks of gestation.
Results Progesterone intervention led to an effect difference of
0.022 (95% CI 0.004 to 0.050) in the trial. The mean cost per
woman in the progesterone group was £76 (95% CI £559 to
£711) more than the mean cost in the placebo group. The
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incremental cost-effectiveness ratio for progesterone compared
with placebo was £3305 per additional live birth. For women with
at least one previous miscarriage, progesterone was more effective
than placebo with an effect difference of 0.055 (95% CI 0.014–
0.096) and this was associated with a cost saving of £322 (95% CI
£1318 to £ 673).
Conclusions The results suggest that progesterone is associated
with a small positive impact and a small additional cost. Both
subgroup analyses were more favourable, especially for women
who had one or more previous miscarriages. Given available
evidence, progesterone is likely to be a cost-effective intervention,
particularly for women with previous miscarriage(s).
Keywords Cost-effectiveness, economic evaluation, miscarriage,
progesterone.
Tweetable abstract Progesterone treatment is likely to be cost-
effective in women with early pregnancy bleeding and a history of
miscarriage.
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Introduction
Miscarriage is defined as the loss of an unborn baby
before the 24th week of pregnancy.1 It is the commonest
adverse outcome of pregnancy,2,3 with 20–25% of
pregnancies ending in a miscarriage.4 Miscarriage is
associated with substantial adverse clinical and psycholog-
ical impacts on women and their families5 and poses
a significant economic burden of an estimated £350 mil-
lion per year to the UK National Health Service
(NHS), for the management of miscarriage and compli-
cations.1,6
Progesterone is a hormone that is naturally secreted by
the ovaries and placenta in early pregnancy and is vital to
the attainment and maintenance of healthy pregnancies.4
Its physiological importance has led clinicians, researchers
and patients to consider progesterone supplementation
during early pregnancy as a miscarriage prevention strategy,
particularly in women at high risk of miscarriage, such as
those with a history of recurrent miscarriages or early preg-
nancy bleeding.7
In 2012, the National Institute for Health and Care
Excellence (NICE) guidelines on ‘Ectopic Pregnancy and
Miscarriage’ called for a large randomised clinical trial to
explore the potential role of progesterone in women with
early pregnancy bleeding.6,8 The PRogesterone In Sponta-
neous Miscarriage (PRISM) trial was funded by the UK
National Institute for Health Research (NIHR) to investi-
gate the effectiveness and cost-effectiveness of progesterone
on pregnancy outcomes in women with first-trimester vagi-
nal bleeding.
We report the economic evaluation carried out alongside
the PRISM trial. The objective of our study is to explore
the relative costs and benefits of using progesterone com-
pared with placebo to prevent miscarriage and achieve a
live birth at or beyond 34 weeks of pregnancy.
Methods
Trial design and participants
The PRISM trial is a multi-centre, randomised, double-
blind, placebo-controlled trial. Detailed information about
the trial design and findings is published elsewhere.7
Briefly, between May 2015 and July 2017, 4153 women
with early pregnancy bleeding and an ultrasonography-con-
firmed intrauterine sac were recruited from 48 hospitals
across the UK.
Inclusion and exclusion criteria are detailed elsewhere7
and are available in the supporting information (see Sup-
plementary material, Appendix S1). Written informed con-
sent was provided by all trial participants. Ethical approval
was obtained from the South Central–Oxford C Research
Ethics Committee (REC ref: 14/SC/1345) and the UK
Health Research Authority. This study is an economic eval-
uation that used data collected from a Clinical Trial, hence
patients were not involved in the development of the study.
The study was funded by the UK NIHR Health Technology
Assessment programme (project number HTA 12/167/26).
Intervention
Women were randomised to either progesterone (400 mg,
i.e. two Utrogestan 200 mg pessaries, twice daily) or identi-
cal placebo pessaries at a 1 : 1 ratio. The pessaries were
administered until 16 full weeks of pregnancy or less if a
termination of pregnancy was confirmed before 16 weeks
of gestation.
Outcomes
Outcomes were assessed at three points: 11–14 weeks of
gestation, end of pregnancy and 28 days after delivery.7
The primary outcome for the cost-effectiveness analysis
(CEA) was live birth at ≥34 completed weeks of gestation.
An additional outcome of the PRISM trial was neonatal
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survival at 28 days postpartum and we explored this as a
secondary outcome in the economic evaluation.
Resource use and costs
Resource use data were collected prospectively using
researcher-recorded data collection forms and health ser-
vices self-completed questionnaires (at registration and trial
end). Resource use data during antenatal and postnatal
periods related to hospital visits, day assessment unit visits,
emergency visits and hospital admissions. For the intra-
partum period, we collected information on the mode of
delivery and pregnancy outcome. Where pregnancy ended
as miscarriage, the management was categorised as sponta-
neous resolution, medical management, or surgical man-
agement. The immediate postnatal care resource use
included the number of nights of maternal admission to a
high dependency unit (HDU) (level 2 care) or intensive
therapy unit (ITU) (level 3 care). Neonatal care resource
use included the number of nights of the neonate receiving
intensive care, high dependency care, or special care. Pri-
mary care resource use included contacts with the general
practitioner, midwife and social care providers such as
social workers. Data were also collected for severe adverse
events occurring during the trial.
Unit costs were identified from established national
sources and are listed in Table 1.9–13 All costs were
expressed in UK pounds sterling using 2017/18 as the base
price year. Where necessary, costs were inflated using the
Hospital and Community Health Services pay and prices
index.14 The cost of progesterone was £21 for a 21-pack,15
translating to a daily cost of £4 (based on the trial’s dosage
of two pessaries twice daily). Ultrasonography costs were
not included because these were equally applied to both
arms of the trial.
The delivery modes were categorised based on the level
of complications,9 and weighted averages of the unit costs
for the different levels of complications were estimated. As
there was no Healthcare Resource Group (HRG) code
available for breech delivery, the cost was assumed (in
agreement with the clinical team) to be the same as the
cost of a normal vaginal delivery. Labour onset costs were
not included as these costs are typically incorporated in the
delivery mode costs. Published definitions for level 2 care
(patient receiving single-organ support) and level 3 care
(patient receiving at least two-organ support),16 were used
to define the costs.9 No clinically specified severe adverse
events were ascribed to the trial, so such costs were not
included.7
Cost-effectiveness analysis
The base-case analysis comprised a within-trial incremental
CEA conducted from an NHS perspective,14 based on the
primary outcome of cost per additional live birth at
≥34 weeks of gestation. The trial time horizon was less than
a year, so discounting was not applied.
An additional and analogous analysis was performed
based on the secondary outcome of neonatal survival at
28 days postpartum. This secondary analysis was reported
in terms of cost per additional baby that survived beyond
28 days of birth.
Costs over the trial period were calculated by multi-
plying the number of resource items used by the corre-
sponding unit cost; these were then added up to obtain
the total cost. To account for the inherent skewness of
cost data, 95% CIs around mean differences were calcu-
lated using the bias-corrected and accelerated bootstrap
method.17
Differences in costs and outcomes between the two com-
parators were calculated using seemingly unrelated estima-
tions.18,19 Regression models were used to control for age,
body mass index, bleeding quantity and number of previ-
ous miscarriages. Incremental cost-effectiveness ratios
(ICERs) were calculated by dividing the difference in mean
cost between the trial arms by the difference in the relevant
outcomes. All statistical analyses were performed using
STATA version 14.20 The economic analysis is reported fol-
lowing the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS).21
Sensitivity and subgroup analyses
To quantify the uncertainty relating to the assumptions
and sampling variations, we conducted sensitivity analyses
including (i) one-way deterministic analyses and (ii) proba-
bilistic sensitivity analyses (PSA). Additionally, (iii) sub-
group analyses were carried out to explore the
characteristics of patients for whom the intervention might
be particularly appropriate.
I. Deterministic sensitivity analyses: The range of deter-
ministic sensitivity analyses performed on the input param-
eters for the base-case included:
1 A fixed cost of intervention until 16 weeks
In the base-case analysis, the intervention cost for each
woman was calculated using the duration of administra-
tion. In practice, progesterone would be provided for the
expected treatment period – from confirmation of preg-
nancy (6–8 weeks) until 16 weeks – hence, we explored
the cost impact of progesterone administered for an
ideal treatment period.
2 Primary-care costs
The base-case analysis adopted an NHS perspective. To
explore the NHS and personal social services perspective,
primary-care costs were included. As there were insuffi-
cient primary-care data, these costs were explored for all
participants by imputing missing costs using multiple
imputations22 by applying chained equations with pre-
dictive mean matching across 60 imputations.23
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3 Unit costs
The costs of antenatal and postnatal inpatient nights of
admission and management termination of pregnancy
used in the base-case analysis were replaced with docu-
mented values8,9,24 that have been used by other
studies.25 Furthermore, the impact of removing delivery
costs from the base-case analysis was explored.
II. Probabilistic sensitivity analysis: This was con-
ducted for the base-case and subgroup analyses. PSA
comprises non-parametric bootstrapping (using seemingly
Table 1. Unit costs of Resource Items (2017/18 prices)
Resource use items Unit cost (£) HRG code Source*
Intervention
Progesterone (Utrogestan) 200 mg 4 n/a BNF15
Antenatal period
Antenatal hospital visit (Routine observation) 468 NZ16Z NHS reference cost9
Antenatal DAU (Specialised non-routine US) 125 NZ22Z NHS reference cost9
Emergency visit (Diagnostic procedures) 118 NZ23Z NHS reference cost11
Inpatient admission <24 hours (Day case management of antenatal disorder) 303 NZ20B NHS reference cost9
Night of patient admission 395 PSSRU13
Delivery mode
Unassisted vaginal delivery (no complications) 1840 NZ30C NHS reference cost9
Unassisted vaginal delivery (complications) 2187 NZ30A, NZ30B NHS reference cost9
Instrumental vaginal delivery (no complications) 2302 NZ40C NHS reference cost9
Instrumental vaginal delivery (complications) 2446 NZ40A, NZ40B NHS reference cost9
Elective caesarean section (no complications) 3257 NZ50C NHS reference cost9
Elective caesarean section (complications) 4079 NZ50A, NZ50B NHS reference cost9
Emergency caesarean section (no complications) 4378 NZ51C NHS reference cost9
Emergency caesarean section (complications) 5678 NZ51A, NZ51B NHS reference cost9
Vaginal breech delivery (no complications) 1840 NZ30C NHS reference cost9
Vaginal breech delivery (complications) 2187 NZ30A, NZ30B NHS reference cost9
Management
Spontaneous resolution (Miscarriage without complications) 619 MB08B NHS reference cost9
Surgical management (Miscarriage with complications) 1880 MB08A NHS reference cost9
Medical management (Miscarriage with complications) 1880 MB08A NHS reference cost9
Postnatal period
Admission to HDU (level 2 care) 965 XC06Z NHS reference cost9
Admission to ITU (level 3 care) 1586 XC01Z-XC05Z NHS reference cost9
Hospital visit 145 n/a PSSRU13
Day assessment unit 125 NZ22Z NHS reference cost9
Emergency visit 98 VB09Z, VB11Z NHS reference cost9
Inpatient admissions (<24 hours) 299 NZ26B NHS reference cost9
Night of inpatient admissions 395 n/a PSSRU13
Neonatal care
Neonatal intensive care 1318 XA01Z NHS reference cost9
Neonatal high dependency care 913 XA02Z NHS reference cost9
Neonatal special care 514 XA03Z-XA04Z NHS reference cost9
Primary-care services (contacts)
GP visits 39 n/a Curtis and Burns10
Practice/Community Midwife 30 n/a Curtis and Burns12
Practice nurse visits 9.5 n/a Curtis and Burns10
Psychologist (or counsellor) visits 20 n/a Curtis and Burns10
Health visitor visits 22 n/a Curtis and Burns12
Social worker visits 20 n/a Curtis and Burns10
Number of other community services 21 n/a Curtis and Burns10
DAU, day assessment unit; GP, general practitioner; NHS, National Health Service; PSSRU, Personal Social Services Unit.
All unit costs are inflated to 2017/18 costs using the UK Hospital and Community Health Services pay and prices index.
*Taken from NHS reference costs (2016/17) unless otherwise stated. Where the NHS categories differ from ours, data were extracted from the
closest match.
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unrelated estimates) to resample the joint distribution in
the mean cost and outcome difference between the two
trial arms.26 This generated 5000 paired estimates of
incremental costs and live births at ≥34 weeks, and cost-
effectiveness planes were generated using scatterplots.27
Cost-effectiveness acceptability curves (CEACs) were con-
structed to illustrate the probability that the intervention
is cost-effective at various monetary values that depict
decision-makers’ willingness to pay for an additional live
birth.14 Detail on the PSA is in the Supplementary mate-
rial (Appendix S2).
III. Subgroup analysis: Two subgroup analyses were
conducted for (i) women with one or more previous mis-
carriage and (ii) women with three or more previous mis-
carriages.
Results
The trial results are reported in detail elsewhere.7 Here, we
provide the key results for the CEA.
Participants
A total of 4153 women were recruited and randomised to
either the progesterone (n = 2079) or placebo (n = 2074)
arm. Thirty (0.7%) women withdrew from the trial and 85
(2%) women were lost to follow up; hence data were avail-
able for 4038 women (2025 in the intervention arm and
2013 in the placebo arm).7
Outcomes
Table 2 presents the results of the trial outcomes required
for the economic analysis. For the primary outcome, the
proportion of women with live births at ≥34 completed
weeks of pregnancy was higher in the progesterone
(74.72%) than the placebo (72.48%) arm – an effect differ-
ence of approximately 0.022 (2.2%) (95% CI 0.004 to
0.050). There were 1605 versus 1533 babies born alive in
the progesterone versus placebo arms, respectively. For the
secondary outcome, babies born to 1538 of the 2025
(75.95%) women in the progesterone arm and 1487 of the
2013 (73.87%) women in the placebo arm were still alive
at 28 days post-birth with an effect difference of 0.021
(2.1%) (95% CI 0.005 to 0.048).
Resource use and costs
A breakdown of the resource use by the trial arm is pro-
vided in the Supplementary material (Table S1). On aver-
age, women in the progesterone arm used the intervention
for a marginally longer period than those in the placebo
arm (50 versus 48 days). For the antenatal period, women
allocated to the progesterone arm had, on average, a higher
frequency of antenatal and day assessment unit visits, but
fewer emergency room visits and hospital admissions than
women in the placebo arm. During the postnatal period,
women in the progesterone arm used similar services more
than those in the placebo arm except for emergency hospi-
tal visits, which were similar for both arms. However,
women in the placebo arm had more admissions to the
HDU and their babies had on average a higher number of
admissions to the HDU and the neonatal special care unit
than in the intervention.7
Table S2 (see Supplementary material) presents the mean
costs per woman by trial arm. The average cost of the trial
intervention was £204 (95% CI £200 to £207) per preg-
nancy. Antenatal hospital visits, with a mean cost of £2339
(SD £2672) and £2334 (SD £2665) per woman for the pro-
gesterone and placebo arms respectively accounted for the
largest proportion of the hospital costs. Mean hospital costs
for mother and infant during the trial period were £7655
(SD £9952) in the progesterone arm and £7572 (SD
£10,616) in the placebo arm, generating a mean cost differ-
ence of £76 (95% CI £559 to £711). Generally, cost dif-
ferences between the trial arms were mostly due to the cost
of the trial intervention itself (£204, 95% CI £200 to £207),
emergency Caesarean section with complications (£137,
95% CI £246 to £281) and neonatal high dependency
care (£93, 95% CI £344 to £159).
Cost-effectiveness analysis
The result of the base-case analysis (Table 3) showed that
the intervention group had a mean cost of £7655 per
woman. The adjusted (bias-corrected and accelerated
Table 2. Outcomes across treatment arms
Outcomes Progesterone Placebo Bootstrap difference (95% CI)
n/N% n/N n/N% n/N
Primary outcome
Live birth beyond 34 weeks 74.72 1513/2025 72.48 1459/2013 0.022 (0.004 to 0.050)
Secondary outcome
Alive 28 days post-delivery 75.95 1538/2025 73.87 1487/2013 0.021 (0.005 to 0.048)
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bootstrapped) mean difference was £76 (95% CI –£559 to
£711) more than the mean per woman cost of the placebo
group (£7572). The progesterone group had a higher pro-
portion of live births at ≥34 weeks, an additional effect of
0.022 (95% CI 0.004 to 0.050), which is equivalent to a
gain of two live births per 100 women. The ICER for pro-
gesterone relative to placebo was £3305 per additional live
birth at ≥34 weeks.
For the secondary analysis, which was based on the sec-
ondary outcome of the PRISM trial (Table 3) (neonatal
survival at 28 days post-partum), progesterone intervention
led to an effect difference of 0.021 (95%CI 0.005 to
0.048), and an ICER of £3037 per additional baby that sur-
vived beyond 28 days post-birth.
Sensitivity analyses
I. Deterministic sensitivity analysis
One-way deterministic sensitivity analyses required varying
costs while keeping the outcome constant. For all scenarios
(see Supplementary material, Table S3), progesterone inter-
vention remained more costly than placebo. The differences
in the estimated ICERs were negligible and unlikely to
impact decision-making.
II. Probabilistic sensitivity analysis
The cost-effectiveness plane for the base-case analysis is
presented in Figure 1. The majority of the scatterplots (de-
picting paired incremental costs and outcomes) are in the
southeast and northeast quadrants. Scatterplots falling in
the southeast quadrant represent improved outcome and
lower costs, whereas scatterplots in the northeast quadrant
represent improved outcome and higher costs. Hence, Fig-
ure 1 suggests that progesterone is a more effective inter-
vention. However, it is uncertain whether progesterone is
likely to be more costly (northeast) or less costly (south-
east) relative to placebo.
The CEAC (Figure 2) shows the probability of proges-
terone being cost-effective at various values of decision-
makers’ willingness to pay (WTP) per additional live birth.
For thresholds of WTP per additional live birth greater
than £15,000, there is >80% probability that progesterone
is cost-effective. The probability of cost-effectiveness stea-
dily increases and exceeds 90% for WTP thresholds greater
than £23,000.
III. Subgroup analysis
The subgroup analysis (Table 4) conducted on women with
at least one previous miscarriage found the trial interven-
tion to be less costly, with a cost saving of £322 (95% CI
£1318 to £673) but more effective with an additional gain
of five live births per 100 women (0.055, 95% CI 0.014–
0.096).
The cost-effectiveness plane (see Supplementary material,
Figure S1A), with the majority of dots in the southeast quad-
rant, suggests that progesterone is less costly and more effec-
tive than placebo. The CEAC (see Supplementary material,
Figure S1B) shows that for WTP thresholds greater than
£20,000, the probability of progesterone being cost-effective
is >90%. The cost-effectiveness plane and CEAC for this sub-
group suggest that progesterone is likely to be considered a
dominant intervention compared with placebo.
For women with three or more previous miscarriages,
progesterone intervention was both more costly (with a
cost difference of £1754, 95% CI –£1041 to £4550) and
more effective (with an additional gain of 15 live births per
100 women). The ICER was £11,606 per additional live
birth at ≥34 weeks. The cost-effectiveness plane for this
subgroup (see Supplementary material, Figure S2A) shows
a majority of the dots in the northeast quadrant, which
represents improved outcome but higher costs. The CEAC
(see Supplementary material, Figure S2B) also shows the
probability of progesterone being cost-effective is >90% for
WTP thresholds greater than £20,000. The differences in
cost compared with both the base-case and the subgroup
Table 3. ICER estimates for the base-case and secondary analysis
Analysis Total cost (£)
per trial arm
Total effect
per trial
arm
ICER
(progesterone
vs placebo –
per additional
live birth
at ≥34 weeks
Base-case analysis (Hospital costs for participants and infants)
Progesterone 7655 0.747 3305
Placebo 7572 0.725
Mean difference
(95% CI)
76
(559 to
711)
0.022
(0.004
to 0.050)
Total cost (£)
per trial arm
Total effect
per trial arm
ICER per
additional
baby
surviving
beyond
28 days
post-partum
Secondary analysis (Hospital costs for participants and
infants)
Progesterone 7655 0.789 3037
Placebo 7572 0.761
Mean difference
(95% CI)
76
(559 to
711)
0.021
(0.005
to 0.048)
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of women with at least one previous miscarriage, were
mostly driven by higher neonatal care costs incurred by
women with three or more previous miscarriages (see
Supplementary material, Figure S3). Although the trial
intervention led to more live births for this group, some of
these babies required neonatal intensive care, HDU or
NW: More costly, 
less effecve 
NE: More costly, 
more effecve  
SW: Less costly, 
less effecve  
SE: Less costly, 
more effecve  
Figure 1. Cost-effectiveness plane for the base-case analysis.
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Figure 2. Cost-effectiveness acceptability curve for the base-case analysis.
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special care, thereby generating a higher cost difference
than the base-case and the other subgroup (see Supplemen-
tary material, Figure S3).
Discussion
Main findings
This study assessed the cost-effectiveness of progesterone
compared with placebo in avoiding miscarriage and achiev-
ing a live birth at ≥34 weeks of pregnancy in women who
presented with bleeding in early pregnancy. The results
suggest that progesterone treatment is more costly with an
average cost per participant of £7655 compared with £7572
for placebo. The difference in costs (£76, 95% CI £559 to
£711) was mainly attributable to the cost of progesterone
(£204). Progesterone resulted in an additional effect of
0.022 (95% CI 0.004 to 0.050).
Although there is statistical uncertainty around the clini-
cal data points, when using the approaches required by the
guidelines for economics analysis,21,28 in which the uncer-
tainty must be estimated using confidence intervals around
the point estimates, the economic analysis suggests that
progesterone has a small positive effect compared with pla-
cebo. Consequently, the base-case economic analysis sug-
gests that progesterone intervention is slightly more costly
and slightly more effective than placebo and the estimated
ICER is £3305 per additional live birth at ≥34 weeks.
In the analogous analysis based on the secondary out-
come (Table 2), the intervention was slightly more effec-
tive, with an estimated gain of two neonates (0.021, 95%
CI 0.005 to 0.048) surviving beyond 28 days post-partum
per 100 women. The ICER was £3037 per additional baby
surviving beyond 28 days post-birth.
The subgroups analyses show a clear result in favour of
progesterone use for women with bleeding and a previous
history of miscarriage. For the subgroup of women with at
least one previous miscarriage, the analysis shows that the
intervention with progesterone would be less costly and
more effective and suggests that progesterone is a dominant
intervention for this group. For the subgroup of women
with three or more previous miscarriages, there is an
increase in the ICER compared with the base-case although
it is still likely to be considered favourable.
It is notable that for the subgroup analyses of women with
three or more previous miscarriages, women in the proges-
terone arm on average incurred more neonatal care costs
than women in the placebo arm. A tentative implication of
this is the success of progesterone, averting miscarriage lead-
ing to more live births requiring neonatal intensive care.
However, the main (base-case) finding showed that overall,
women in the placebo arm on average used more neonatal
care resources than those in the progesterone arm.
Strengths and limitations
A strength of this economic evaluation is that it is based
on the largest multi-centre randomised clinical trial (over
4000 participants), which explored whether progesterone is
clinically effective in preventing miscarriage in women with
early pregnancy bleeding. The data were prospectively col-
lected at different points in the trial. Unit costs were
obtained from standard and recognised sources. The cost-
effectiveness results also benefited from the robustness of
the main analyses and sensitivity analyses.7 Although data
on primary-care services were available for <10% of the
participants this was accounted for by imputing missing
costs.
A potential limitation of this study is the confusion that
might arise given that the reported clinical results for the
base-case suggested the additional effect of progesterone
was not statistically significantly different from the pla-
cebo,7 whereas the health economics analysis suggests that
progesterone given to women who have threatened miscar-
riage in early pregnancy is likely to be cost-effective. This
contrasting interpretation of the results relates to a
Table 4. Results of the subgroup analyses
Analysis Total cost (£) per trial arm Total effect per trial arm ICER (progesterone vs
placebo – per additional
live birth at ≥34 weeks
Subgroup analysis (Hospital costs for participants with at least one previous miscarriage)
Progesterone 7705 0.754 Progesterone dominant
Placebo 8072 0.699
Mean difference (95% CI) 322 (1318 to 673) 0.055 (0.014 to 0.096)
Subgroup analysis (Hospital costs for participants with three or more previous miscarriages)
Progesterone 9304 0.715 11 606
Placebo 7803 0.574
Mean difference (95% CI) 1754 (1041 to 4550) 0.151 (0.042 to 0.260)
8 ª 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of
Royal College of Obstetricians and Gynaecologists
Okeke Ogwulu et al.
requirement in the recommendations for health economics
analysis to estimate and quantify the uncertainty around
the clinical end-points (based on appropriate distributions
applied to the confidence intervals surrounding the point
estimate and using probabilistic sensitivity analysis).21,28
This recommended and widely endorsed approach to esti-
mating the uncertainty is recognised as potentially challeng-
ing and has been widely debated and explained
elsewhere.14,28,29 This approach, advocated in health eco-
nomics guidelines14,21 has very recently received attention
and support from elsewhere.30,31
It was beyond the scope of and timeline of this study to
explore the wider societal costs to the participants, given
the potential impact on society of fewer miscarriages but
the wider societal perspective is not anticipated to oppose
the direction of the results reported here.
Interpretation
Whether progesterone would be supported in resource allo-
cation decisions depends on the amount that society is
willing to pay to increase the chances of an additional live
birth at ≥34 weeks of gestation. There is currently no
threshold values assigned to an additional live birth.25,32
The base-case analysis (Figure 2) suggests that the probabil-
ity of progesterone being cost-effective is >50% for almost
all values represented in the CEAC. The subgroup analysis
for at least one miscarriage (see Supplementary material,
Figure S1B) is more convincing. Given the distress to
women and families associated with miscarriage, and the
subsequent resources that might be associated with coun-
selling and close antenatal attention in the subsequent
pregnancies of women who experience miscarriage,33 the
costs of which were beyond the remit of the current study,
progesterone is likely to be considered good value for
money in preventing miscarriage.
Comparison with the literature
This is the first UK research to examine the cost-effectiveness
of progesterone in achieving a live birth beyond 34 weeks in
women with threatened miscarriage. A similar UK study
explored the cost-effectiveness of progesterone in preventing
miscarriages in women with a history of unexplained recur-
rent miscarriages leading to a live birth beyond 24 weeks.25
The authors found that the total mean cost of the interven-
tion was higher in the progesterone arm than in the placebo
arm by £332 and an ICER of £18,053 per additional live birth
beyond 24 weeks for the base-case analysis with a 50% prob-
ability of being cost-effective at this value.25
Conclusion
Currently, in the UK, progesterone is not routinely given
to women who are at high risk for a miscarriage.6 The
results of the CEA reported here suggest that progesterone
is likely to be cost-effective for all women at risk, but par-
ticularly for women with one or more previous miscar-
riages who present with bleeding in early pregnancy. This
analysis lends credibility to the belief that progesterone
should be given to such women7 on cost-effectiveness
grounds.
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